It has consistently been reported that a higher rate of TP53 mutation has been identified in breast cancer patients at advanced stages or with aggressive characteristics, including the subtype of triple negative or HER2 amplified cases.30, 31 However, our data only supported the effect of HR/HER2 status on TP53, but did not find the effect of tumor stage on TP53, which may be related to the small number of cases included in the cohort of GDPH stage IV breast cancer patients, or other reasons. The gene discussed is ERBB2; the disease is breast carcinoma.